Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

, REGN

Regeneron

$402.82

0.8 (0.20%)

10:26
10/04/16
10/04
10:26
10/04/16
10:26

Before the Move: Ophthotech worries seen as opportunity ahead of Phase 3 data

Regeneron Pharmaceuticals' (REGN) disappointing Phase 2 data evaluating aflibercept co-formulated with rinucumab in neovascular age-related macular degeneration, or AMD, released on Friday have been a drag on shares of Ophthotech (OPHT), which are down about 15% over the last few sessions. The latter is also focused on developing therapeutics for AMD, but JPMorgan analyst Anupam Rama believes the treatments being developed by the companies show "important differences." Further, the analyst recommended buying Ophthotech's shares amid the weakness ahead of its Phase 3 data, which is expected to be released before the end of the year. BACKGROUND: Ophthotech has initiated a pivotal Phase 3 clinical program to evaluate Fovista 1.5mg combination with anti-VEGF drugs compared to anti-VEGF monotherapy for the treatment of newly diagnosed patients with wet AMD, which is the more advanced type of the disease. Although it affects only 10%-15% of those who have the condition, it accounts for 90% of the severe vision loss caused by macular degeneration. BUY ON WEAKNESS: In a note to investors this morning, JPMorgan's Rama raised his price target for Ophthotech to $110 from $95, citing the elimination of its key competitor Regeneron from the Wet AMD space following its trial failure. Noting that Ophthotech's stock was down amid mechanism concerns following Regeneron's data, Rama said he views the weakness as a buying opportunity. Further, he sees "important mechanistic differences" between the company's Fovista and Regeneron's REGN2176-3, adding that early Phase 1 data for Fovista is "comparatively more compelling." Rama told investors that Ophthotech's Phase 3 results with Fovista and Lucentis combination therapy are expected this quarter, and reiterated an Outperform rating on the company's shares. COMPETITOR DATA: On Friday, Regeneron announced topline results from its Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an anti-platelet-derived growth factor receptor beta antibody, in patients with neovascular AMD. The combination therapy did not demonstrate an improvement in best corrected visual acuity compared to intravitreal aflibercept injection monotherapy at 12 weeks, the primary endpoint of the study. PRICE ACTION: In morning trading, shares of Ophthotech's shares have gained about 5.5% to $45.97, while Regeron's stock is flat near $402 per share. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.

OPHT

Ophthotech

$43.57

-2.56 (-5.55%)

REGN

Regeneron

$402.82

0.8 (0.20%)

  • 30

    Oct

  • 29

    Mar

OPHT Ophthotech
$43.57

-2.56 (-5.55%)

10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
06/02/16
JPMS
06/02/16
UPGRADE
Target $84
JPMS
Overweight
Ophthotech upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Ophthotech to Overweight saying the Fovista phase 3 Lucentis combination studies reading out in Q4 have a very high probability of success. The analyst's base case assumes a four-plus letter gain in visual acuity compared to Lucentis monotherapy, resulting in 55%-60% share upside. His "homerun scenario," or five-plus letter, results in 150% share upside. He raised his price target for Ophthotech shares to $84 from $60.
REGN Regeneron
$402.82

0.8 (0.20%)

10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.

TODAY'S FREE FLY STORIES

NUS

Nu Skin

$51.56

0.05 (0.10%)

07:32
12/07/16
12/07
07:32
12/07/16
07:32
Hot Stocks
Nu Skin announces CEO transition plan »

Nu Skin Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CAL

Caleres

$33.80

0.28 (0.84%)

07:31
12/07/16
12/07
07:31
12/07/16
07:31
Upgrade
Caleres rating change  »

Caleres upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

, CMCSA

Comcast

$68.70

0.02 (0.03%)

07:31
12/07/16
12/07
07:31
12/07/16
07:31
Conference/Events
UBS to hold a conference »

44th Annual Global Media…

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

CMCSA

Comcast

$68.70

0.02 (0.03%)

AMT

American Tower

$100.85

-1.19 (-1.17%)

HSNI

HSN, Inc.

$35.90

-0.2 (-0.55%)

TGNA

TEGNA

$22.63

0.35 (1.57%)

CNSL

Consolidated Communications

LBTYA

Liberty Global

$29.91

0.36 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

TEVA

Teva

$35.03

-2.01 (-5.43%)

, COG

Cabot Oil & Gas

$23.57

-0.06 (-0.25%)

07:30
12/07/16
12/07
07:30
12/07/16
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TEVA

Teva

$35.03

-2.01 (-5.43%)

COG

Cabot Oil & Gas

$23.57

-0.06 (-0.25%)

FTK

Flotek

$13.11

-0.47 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 03

    Apr

07:30
12/07/16
12/07
07:30
12/07/16
07:30
General news
Treasury Market Outlook: bond yields are several ticks lower globally »

Treasury Market Outlook:…

CBS

CBS

$60.97

0.16 (0.26%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Recommendations
CBS analyst commentary  »

CBS remains a top pick at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

P

Pandora

$13.78

0.41 (3.07%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Recommendations
Pandora analyst commentary  »

Pandora Premium will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNCE

Snyder's-Lance

$36.81

0.23 (0.63%)

, LVS

Las Vegas Sands

$62.47

1.35 (2.21%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Conference/Events
Bernstein to hold a summit »

3rd Annual Consumer…

LNCE

Snyder's-Lance

$36.81

0.23 (0.63%)

LVS

Las Vegas Sands

$62.47

1.35 (2.21%)

SAP

SAP

$82.99

-0.14 (-0.17%)

TSN

Tyson Foods

$57.39

0.12 (0.21%)

TUP

Tupperware Brands

$55.46

0.24 (0.43%)

CDXC

ChromaDex

$2.39

0.05 (2.14%)

TVIA

Tvia, Inc.

$1.25

0.1 (8.70%)

HRL

Hormel Foods

$33.31

-0.48 (-1.42%)

RCL

Royal Caribbean

$81.15

0.1 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 09

    Jan

RKDA

Arcadia Biosciences

, SEED

Origin Agritech

$2.50

0.02 (0.81%)

07:28
12/07/16
12/07
07:28
12/07/16
07:28
Conference/Events
UBS to hold a conference »

2016 UBS Agriculture Day…

RKDA

Arcadia Biosciences

SEED

Origin Agritech

$2.50

0.02 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

OSIS

OSI Systems

$76.45

0.51 (0.67%)

, ZIXI

ZixCorp

$4.45

0.03 (0.68%)

07:27
12/07/16
12/07
07:27
12/07/16
07:27
Conference/Events
Imperial Capital to hold a conference »

2016 Security Investor…

OSIS

OSI Systems

$76.45

0.51 (0.67%)

ZIXI

ZixCorp

$4.45

0.03 (0.68%)

APDN

Applied DNA Sciences

$2.25

0.05 (2.27%)

ASCMA

Ascent Capital

$18.00

-0.19 (-1.04%)

BCO

Brink's

$39.95

0.9 (2.30%)

CTRL

Control4

$11.20

0.01 (0.09%)

NSSC

NAPCO Security

$8.15

0.15 (1.88%)

VRNT

Verint

$38.20

0.15 (0.39%)

INVE

Identiv

$2.58

0.11 (4.45%)

QLYS

Qualys

$32.25

-0.25 (-0.77%)

TASR

TASER

$28.19

0.11 (0.39%)

PCTI

PCTEL

$5.06

0.09 (1.81%)

RDWR

Radware

$13.64

0.07 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CGEN

Compugen

$6.10

0.1 (1.67%)

07:26
12/07/16
12/07
07:26
12/07/16
07:26
Hot Stocks
Compugen discloses cancer immunotherapy program for TIGIT »

Compugen disclosed today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$14.69

1.01 (7.38%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Conference/Events
Credit Suisse to hold a conference »

2016 Quantitative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

EW

Edwards Lifesciences

$83.22

0.73 (0.88%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ARGS

Argos Therapeutics

$4.75

0.05 (1.06%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Conference/Events
Argos Therapeutics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TCRD

THL Credit

$10.32

-0.02 (-0.19%)

, FSIC

FS Investment

$10.05

-0.05 (-0.50%)

07:24
12/07/16
12/07
07:24
12/07/16
07:24
Conference/Events
Wells Fargo to hold a forum »

2016 Middle Market…

TCRD

THL Credit

$10.32

-0.02 (-0.19%)

FSIC

FS Investment

$10.05

-0.05 (-0.50%)

BKCC

BlackRock Capital Investment

$7.41

0.08 (1.09%)

NMFC

New Mountain Finance

$14.20

-0.05 (-0.35%)

SLRC

Solar Capital

$20.67

0.14 (0.68%)

TCPC

TCP Capital

$16.95

-0.03 (-0.18%)

MAIN

Main Street

$36.37

-0.04 (-0.11%)

TSLX

TPG Specialty Lending

$18.49

0.12 (0.65%)

HTGC

Hercules Capital

$13.62

-0.12 (-0.87%)

KKR

KKR

$15.87

0.2 (1.28%)

TROW

T. Rowe Price

$76.09

0.51 (0.67%)

APO

Apollo Global

$19.28

0.03 (0.16%)

BX

Blackstone

$26.55

0.15 (0.57%)

GS

Goldman Sachs

$231.38

2.83 (1.24%)

WFC

Wells Fargo

$55.55

1.2 (2.21%)

ARCC

Ares Capital

$16.31

0.17 (1.05%)

MCC

Medley Capital

$7.63

-0.04 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 15

    Dec

WDC

Western Digital

$63.85

1.76 (2.83%)

07:24
12/07/16
12/07
07:24
12/07/16
07:24
Recommendations
Western Digital analyst commentary  »

Brean Capital ups Western…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LW

Lamb Weston

$33.82

0.17 (0.51%)

07:23
12/07/16
12/07
07:23
12/07/16
07:23
Recommendations
Lamb Weston analyst commentary  »

Lamb Weston should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FI

Frank's International

$12.51

-0.09 (-0.71%)

07:21
12/07/16
12/07
07:21
12/07/16
07:21
Syndicate
Breaking Syndicate news story on Frank's International »

Frank's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMO

Bank of Montreal

$69.33

1.85 (2.74%)

07:21
12/07/16
12/07
07:21
12/07/16
07:21
Upgrade
Bank of Montreal rating change  »

Bank of Montreal upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$57.92

0.64 (1.12%)

07:21
12/07/16
12/07
07:21
12/07/16
07:21
Periodicals
Citi says operations ran properly in sterling 'flash crash,' Reuters reports »

Citi said its trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 26

    Jan

EVHC

Envision Healthcare

$71.70

-0.05 (-0.07%)

07:20
12/07/16
12/07
07:20
12/07/16
07:20
Upgrade
Envision Healthcare rating change  »

Envision Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

07:20
12/07/16
12/07
07:20
12/07/16
07:20
General news
FX Update: The dollar settled at near net unchanged levels »

FX Update: The dollar…

BMY

Bristol-Myers

$56.03

0.48 (0.86%)

, ARAY

Accuray

$5.05

0.1 (2.02%)

07:18
12/07/16
12/07
07:18
12/07/16
07:18
Conference/Events
Citigroup to hold a conference »

2016 Global Healthcare…

BMY

Bristol-Myers

$56.03

0.48 (0.86%)

ARAY

Accuray

$5.05

0.1 (2.02%)

AERI

Aerie Pharmaceuticals

$40.40

0.1 (0.25%)

AMGN

Amgen

$145.11

-0.18 (-0.12%)

ALXN

Alexion

$124.17

-0.76 (-0.61%)

MRK

Merck

$60.28

0.03 (0.05%)

MD

MEDNAX

$67.05

1.13 (1.71%)

PKI

PerkinElmer

$52.10

0.95 (1.86%)

CYH

Community Health

$5.73

0.22 (3.99%)

TSRO

TESARO

$139.87

0.31 (0.22%)

AGN

Allergan

$190.94

-0.24 (-0.13%)

ISRG

Intuitive Surgical

$621.59

-15.36 (-2.41%)

VNRX

VolitionRx

$4.31

-0.08 (-1.82%)

OPK

OPKO Health

$11.33

0.54 (5.00%)

NVO

Novo Nordisk

$35.26

0.84 (2.44%)

HRC

Hill-Rom

$55.02

0.95 (1.76%)

CYTK

Cytokinetics

$11.30

0.05 (0.44%)

ACRS

Aclaris Therapeutics

$30.55

0.4 (1.33%)

UHS

Universal Health

$126.37

1.59 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

  • 11

    Jan

  • 08

    Mar

  • 19

    Jul

BBG

Bill Barrett

$8.01

0.12 (1.52%)

07:18
12/07/16
12/07
07:18
12/07/16
07:18
Syndicate
Bill Barrett 13.5M share Spot Secondary priced at $7.40 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

07:17
12/07/16
12/07
07:17
12/07/16
07:17
General news
Futures trading near fair value »

Stock futures are trading…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.